Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces positive tuberous sclerosis drug trial data

Novartis announces positive tuberous sclerosis drug trial data

8th July 2011

Novartis has published positive clinical trial data from a phase III study of everolimus as a treatment for tuberous sclerosis.

Data from the Exist-1 clinical study showed that more than one-third of patients utilising the treatment saw a reduction in the size of subependymal giant cell astrocytomas by 50 percent or more.

This represents the largest study conducted to date for this condition, which affects between one and two million people worldwide and can only be treated using brain surgery in countries where everolimus is not approved.

Novartis is currently seeking approval of the drug in this specification in Europe, where it will be marketed under the name Votubia.

Herve Hoppenot, president of Novartis Oncology, said: "This outcome is welcome news as we continue our research efforts to fully understand the potential of this important treatment option."

Earlier this week, the company published trial data showing the potential efficacy of everolimus as a therapy for advanced breast cancer.ADNFCR-8000103-ID-800615775-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.